公开(公告)号：US07501494B2

公开(公告)日：2009-03-10

申请号：US10342959

申请日：2003-01-15

申请人： Shugene Lynn ,  Chang Yi Wang

发明人： Shugene Lynn ,  Chang Yi Wang

IPC分类号： C07K16/00 ,  A61K39/395

CPC分类号： C07K16/2812 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/567 ,  C07K2317/76

摘要： This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.

摘要翻译： 本发明涉及可用作针对人类免疫缺陷病毒（HIV）和CD4介导的自身免疫性疾病的免疫治疗药物的去免疫化抗体。 更具体地，由克隆表达的抗体，含有重组基因B4DIVHv1 / VK1CHO＃7的克隆7，含有重组基因B4DIVHv1 / VK1＃16的克隆16和含有重组基因B4DIVHv1 / VK1＃21的克隆21衍生自小鼠单克隆 B4抗体（mAb B4）。 通过除去由人免疫系统识别为外源的特异性小鼠决定簇来产生抗体。 这些重组抗体是通过小鼠单克隆抗体（mAb）B4的Fv区的嵌合和解除免疫产生的。 为了改善安全性，编码序列可进一步突变以表达不能结合补体的糖基化IgG1抗体。 解除免疫的抗体保留鼠单克隆抗体B4对宿主T细胞表面上涉及CD4的受体复合物的特异性，并保持mAb B4的特征性能力来中和HIV的初级分离物。

公开(公告)号：US07872110B2

公开(公告)日：2011-01-18

申请号：US12207034

申请日：2008-09-09

申请人： Shugene Lynn ,  Chang Yi Wang

发明人： Shugene Lynn ,  Chang Yi Wang

IPC分类号： C07H23/00 ,  A61K39/395 ,  C12N15/09

CPC分类号： C07K16/2812 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/567 ,  C07K2317/76

摘要： This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.

摘要翻译： 本发明涉及可用作针对人类免疫缺陷病毒（HIV）和CD4介导的自身免疫性疾病的免疫治疗药物的去免疫化抗体。 更具体地，由克隆表达的抗体，含有重组基因B4DIVHv1 / VK1CHO＃7的克隆7，含有重组基因B4DIVHv1 / VK1＃16的克隆16和含有重组基因B4DIVHv1 / VK1＃21的克隆21衍生自小鼠单克隆 B4抗体（mAb B4）。 通过除去由人免疫系统识别为外源的特异性小鼠决定簇来产生抗体。 这些重组抗体是通过小鼠单克隆抗体（mAb）B4的Fv区的嵌合和解除免疫产生的。 为了改善安全性，编码序列可进一步突变以表达不能结合补体的糖基化IgG1抗体。 解除免疫的抗体保留鼠单克隆抗体B4对宿主T细胞表面上涉及CD4的受体复合物的特异性，并保持mAb B4的特征性能力来中和HIV的初级分离物。

公开(公告)号：US20050214748A1

公开(公告)日：2005-09-29

申请号：US10983854

申请日：2004-11-08

申请人： Chang Wang ,  Xinde Fang ,  Tseng Chang ,  Scott Liu ,  Shugene Lynn ,  Charles Sia

发明人： Chang Wang ,  Xinde Fang ,  Tseng Chang ,  Scott Liu ,  Shugene Lynn ,  Charles Sia

IPC分类号： C07K20060101 ,  C12Q1/70

CPC分类号： G01N33/56983 ,  C12N2770/20021 ,  G01N2333/165 ,  G01N2469/20

摘要： The present invention is directed to antigenic peptides and peptide compositions selected from the Membrane glycoprotein (M), the Spike glycoprotein (S), and the Nucleocapsid (N) protein antigens of the SARS coronavirus (SCoV). The present invention is also directed to methods of use of the peptides of the invention, e.g., for the detection of SARS-associated antibodies. Detection methods include enzyme-linked immunosorbent assay (ELISA) or other immunoassay procedures.

摘要翻译： 本发明涉及选自SARS冠状病毒（SCoV）的膜糖蛋白（M），Spike糖蛋白（S）和Nucleocapsid（N）蛋白抗原的抗原肽和肽组合物。 本发明还涉及使用本发明的肽的方法，例如用于检测SARS相关抗体。 检测方法包括酶联免疫吸附测定（ELISA）或其他免疫测定方法。

公开(公告)号：US20090060914A1

公开(公告)日：2009-03-05

申请号：US12207034

申请日：2008-09-09

申请人： Shugene Lynn ,  Chang Yi Wang

发明人： Shugene Lynn ,  Chang Yi Wang

IPC分类号： A61K39/395 ,  C07H21/04 ,  C12N5/10

CPC分类号： C07K16/2812 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/567 ,  C07K2317/76

摘要： This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.

摘要翻译： 本发明涉及可用作针对人类免疫缺陷病毒（HIV）和CD4介导的自身免疫性疾病的免疫治疗药物的去免疫化抗体。 更具体地，由克隆表达的抗体，含有重组基因B4DIVHv1 / VK1CHO＃7的克隆7，含有重组基因B4DIVHv1 / VK1＃16的克隆16和含有重组基因B4DIVHv1 / VK1＃21的克隆21衍生自小鼠单克隆 B4抗体（mAb B4）。 通过除去由人免疫系统识别为外源的特异性小鼠决定簇来产生抗体。 这些重组抗体是通过小鼠单克隆抗体（mAb）B4的Fv区的嵌合和解除免疫产生的。 为了改善安全性，编码序列可进一步突变以表达不能结合补体的糖基化IgG1抗体。 解除免疫的抗体保留鼠单克隆抗体B4对宿主T细胞表面上涉及CD4的受体复合物的特异性，并保持mAb B4的特征性能力来中和HIV的初级分离物。

公开(公告)号：US20050100883A1

公开(公告)日：2005-05-12

申请号：US10712812

申请日：2003-11-12

申请人： Chang Wang ,  Xinde Fang ,  Tseng Chang ,  Scott Liu ,  Shugene Lynn ,  Charles Sia

发明人： Chang Wang ,  Xinde Fang ,  Tseng Chang ,  Scott Liu ,  Shugene Lynn ,  Charles Sia

IPC分类号： A61K38/00 ,  A61K38/16 ,  C07K14/165 ,  C12Q1/70 ,  G01N33/569

CPC分类号： C07K14/005 ,  A61K38/00 ,  C12N2770/20022 ,  G01N33/56983

摘要： The present invention is directed to antigenic peptides and peptide compositions selected from the Membrane glycoprotein (M), the Spike glycoprotein (S), and the Nucleocapsid (N) protein antigens of the SARS coronavirus (SCoV). The present invention is also directed to methods of use of the peptides of the invention, e.g., for the detection of SARS-associated antibodies. Detection methods include enzyme-linked immunosorbent assay (ELISA) or other immunoassay procedures.